PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Active — Not RecruitingPhase 2

NCT04980872

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who A…

This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-…

United States60 participantsStarted 2021-11-02

Treatment: Miransertib